Cellectis S.A. - דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים CLLS

The year-over-year percentage change in sales volume for the LTM on the GURU.Markets terminal analytical chart illustrates revenue dynamics, where the -0.10 level indicates the parameter's status. Cellectis S.A. (CLLS) minimizes production outsourcing through its own capacities, although it relies on external researchers. Amidst fierce patent battles and a lack of stable assets, the company's financial health depends entirely on the outcomes of current clinical trials.

Fundamental asset selection requires an analysis of revenue dynamics to identify the business expansion phase by comparing current and prior periods. The -0.10 metric measures the percentage change in sales volume over the last twelve months, which for the allogeneic CAR-T therapy pioneer Cellectis S.A. (CLLS) reflects the commercialization pace of "off-the-shelf" drugs, as indicated by this TTM annual sales growth chart.